Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-@tamoxifen

IDENTIFICATION NUMBERS

- **CAS:** 10540-29-1
- **EC/EINECS:** 234-118-0

MORE INFORMATION

- **Molecular Formula:** C26-H29-N-O

CLASSIFICATION AND LABELLING (Regulation 1272/2008)

No classifications available

Specific health risks

Carcinogens (other sources)

Substances classified as carcinogens or mutagens Category 3 under the Dangerous Preparations Directive criteria (pre-CLP). Substances with limited evidence or indications of carcinogenicity or mutagenicity.

CATEGORY	SOURCE
CP, N-1	CP65, NTP

Neurotoxic substances

Substances with neurotoxic effects

LEVEL

1

According to IARC

Substances classified as carcinogens or mutagens Category 2 under the CLP Regulation (GHS), bearing H351 and/or H341 phrases. These are substances suspected of causing cancer or heritable genetic mutations in humans.

IARC GROUP	IARC VOLUME
Grupo 1	66, 100A; 2012

IARC NOTES

There is also conclusive evidence that tamoxifen reduces the risk of contralateral breast cancer in breast cancer patients

Restriction/prohibition regulations

Substances under PACT evaluation

Substances under active regulatory monitoring through ECHA's PACT (Public Activities Coordination Tool). Allows tracking which regulatory authorities are examining a substance and what potential regulatory actions are being considered (restriction, SVHC identification, harmonised classification, etc.).

MEMBER STATE	ACTIVITY
COM	Hazard assessment
LAST UPDATE	**SCOPE**
2015-04-01T00:00:00	PBT